NewsNovo
When pharmaceutical companies take each other to court, the litigation becomes an investment variable as real as the balance sheet.
Eli Lilly (LLY) has said it will vigorously defend itself against a lawsuit filed by Novo Nordisk (NVO) and intends to keep scientific research at the center of its operations. The posture signals confidence.
What complicates it is that the substance of the dispute, and its full implications, remains unknown. Lilly's stated position Lilly's response was pointed in two directions at once.
The company affirmed its intent to fight the lawsuit aggressively while simultaneously committing to prioritize scientific work, a pairing that amounts to a message: this legal challenge will not set the company's agenda.
Keep reading